Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
Lantern Pharma (NASDAQ: LTRN) announced it will present new findings on LP-184, a targeted small molecule for prostate cancer, at the AACR Virtual Annual Meeting from April 10-15, 2021. The data highlights LP-184's effectiveness against DNA damage repair defects found in 25-30% of metastatic prostate cancer patients. CEO Panna Sharma noted the potential for LP-184 to exhibit best-in-class efficacy, particularly in tumors with specific genetic mutations. The findings will be showcased in a poster presentation during the conference.
- None.
- None.
DALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.
Lantern's poster will highlight the spectrum of DNA damage repair defects, occurring in 25
Details of the abstract are as follows:
Title: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents
Permanent Abstract Number: 1249
The full text of the abstract is now available on the AACR Annual Meeting 2021 website.
The accompanying poster will be available to view to registered participants during the conference via the AACR e-poster website on April 10, 2021, and published on the company website after the conference.
Contact
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company leveraging advances in genomics, artificial intelligence, and machine learning by using our proprietary RADR® A.I. platform to discover biomarker signatures that identify patients most likely to respond to our pipeline of cancer therapeutics. Our collaborator-centered business model seeks out industry partners and leading scientific advisors to capital-efficiently develop our pipeline of targeted cancer therapeutics. Lantern is currently developing four drug candidates and an ADC program across seven disclosed targets, including two phase 2 programs, all focused on cancers with unique and unmet clinical needs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. More information is available at www.lanternpharma.com and Twitter @lanternpharma.
About LP-184
LP-184 is currently in multiple research studies in collaboration with leading cancer research institutions. With the assistance of our RADR® A.I. platform, LP-184's mechanism of action has been well-characterized through numerous in-silico and in-vivo studies and described in published peer-reviewed articles. With observed nanomolar potency and blood brain barrier permeability, LP-184 is an alkylating agent that works by causing preferential DNA damage in certain tumor cells. As shown by CRISPR gene editing techniques, LP-184 activity is dependent upon the expression of Prostaglandin Reductase 1 ("PTGR1"), which transforms LP-184 into its bioactive form by the oxidoreductase activity of PTGR1. Additional information on LP-184 is available at: Oncology Drug Development Pipeline - Lantern Pharma.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators in the area of ATRT may not be successful; (iii) the risk that we may never receive a Rare Pediatric Disease Designation for LP-184 in ATRT and may never qualify for the grant of a Rare Pediatric Disease Priority Review Voucher (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates; (v) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-present-new-data-supporting-the-advancement-of--lp-184-at-the-aacr-virtual-annual-meeting-2021-301253790.html
SOURCE Lantern Pharma
FAQ
What is LP-184 and its significance for prostate cancer?
When will Lantern Pharma present new data on LP-184?
What percentage of metastatic prostate cancer patients could benefit from LP-184?
Who is collaborating with Lantern Pharma on LP-184 research?
What are the key findings regarding LP-184's potency?
